scholarly journals A Case of Angiotropic Large Cell Lymphoma Primarily Discovered in Biopsy Specimens from Liver and Bone Marrow

1999 ◽  
Vol 8 (1) ◽  
pp. 69-72 ◽  
Author(s):  
M. Kahvic ◽  
N.C. Nayak ◽  
S. Mokhtar ◽  
A.S. Dhamer ◽  
A.R.D. Lulu
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Biopsy Specimens ◽  
Large Cell Lymphoma

Assessment of bone marrow status in diffuse B-cell large cell lymphoma: PET/CT capabilities

2021 ◽  
pp. 14-20
Author(s):  
N. A. Ognerubov ◽  
T. S. Antipova ◽  
A. V. Blokhin
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Metabolic Imaging ◽  
Focal Lesions ◽  
Pet Ct ◽  
Bone Marrow Damage ◽  
Large Cell Lymphoma ◽  
Histological Confirmation

The aim of this work was to present the results of a retrospective study of 35 patients with morphologically diagnosed diffuse B-cell large cell lymphoma with bone marrow damage from 22 to 82 years old, median 63 years. There were 27 men and 8 women. After histological confirmation, all patients performed positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose (FDG PET/CT) followed by bone marrow trepanobiopsy. Specific bone marrow lesions were detected in 100% of cases with PET/CT and in 68.6% of cases with trepanobiopsy. Diffuse bone marrow damage was detected in 24 (68.6%) cases, focal – in 10 (28.6%) patients and in 1 (2.8%) patient – a mixed variant. The data obtained indicate the predominance of diffuse damage to the bone marrow. The statistical analysis established the value of the standardized maximum absorption coefficient of FDG SUVmax for bone marrow damage equal more than 3.58. Sensitivity was at 90% and a specificity was at 92%. The sensitivity of the PET/CT method is higher with focal lesions of the bone marrow than with diffuse. SUVmax was 10.26 ± 1.67 and 2.86 ± 0.09, respectively. The differences between them are significant (p < 0.0001). PET/CT is a non-invasive method of metabolic imaging allows you to assess the condition of the bone marrow and other extranodal symptoms of the disease at the stage of diagnosis, treatment and follow-up. It can replace the traditional method of bone marrow biopsy with diffuse B-cell large cell lymphoma.

Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse.

1991 ◽  
Vol 9 (2) ◽  
pp. 236-242 ◽  
Author(s):  
L E Robertson ◽  
J R Redman ◽  
J J Butler ◽  
B M Osborne ◽  
W S Velasquez ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Lymph Node Biopsy ◽  
High Rate ◽  
Late Relapse ◽  
Diffuse Large Cell Lymphoma ◽  
Large Cell Lymphoma ◽  
Risk Of Relapse

From 1975 to 1988, 50 patients with lymph node biopsy-documented diffuse large-cell lymphoma (DLCL) presented with bone marrow involvement. Twenty-four patients (48%) had large-cell lymphoma (LCL) in the bone marrow and were compared with 19 (38%) patients who had small cleaved-cell lymphoma (SCCL) in the marrow. Additionally, seven patients (14%) had mixed small- and large-cell lymphoma (ML) in the marrow. Patients who had LCL marrow involvement were younger (P less than .02) and more frequently had elevated lactic dehydrogenase (LDH) levels (P less than .001), high tumor burden (P less than .01), and more sites of extranodal disease (P less than .05) than those with SCCL in the marrow. The complete response (CR) rate to multiagent chemotherapy was 16.7% in the LCL group and 89.4% in the SCCL group (P less than .001). One third of the patients with LCL in the marrow developed CNS involvement, compared with only one patient in the SCCL group (P = .06). Overall 5-year survival was 79% in patients with SCCL marrow involvement, compared with only 12% in patients with LCL in the marrow (P = .002). Despite a high CR rate, patients with marrow involved by SCCL were at a high continuous risk of relapse with only a 30% failure-free survival at 5 years. We conclude that bone marrow involvement with LCL predicts for extremely poor prognosis with low response rate and short survival. Patients with SCCL in the bone marrow have a high rate of CR and a high rate of 5-year survival; however, there is a high risk of late relapse, and only 15% are in a continuous remission at 8 years.

Delphi-Panel Analysis of Appropriateness of High-Dose Chemotherapy and Blood Cell or Bone Marrow Autotransplants in Diffuse Large-Cell Lymphoma

1998 ◽  
Vol 32 (1-2) ◽  
pp. 139-149 ◽  
Author(s):  
Robert Peter Gale ◽  
Rolla Edward Park ◽  
Robert Dubois ◽  
Philip Jay Bierman ◽  
Richard I. Fisher ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Blood Cell ◽  
Cell Lymphoma ◽  
Large Cell ◽  
High Dose Chemotherapy ◽  
Delphi Panel ◽  
High Dose ◽  
Panel Analysis ◽  
Diffuse Large Cell Lymphoma ◽  
Large Cell Lymphoma

Large cell lymphoma with initial presentation in the bone marrow

1992 ◽  
Vol 10 (5) ◽  
pp. 261-271 ◽  
Author(s):  
K. F. Wong ◽  
J. K. C. Chan ◽  
C. S. Ng ◽  
Y. C. Chu ◽  
L. P. K. Li ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Initial Presentation ◽  
Large Cell Lymphoma

scholarly journals Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma

2003 ◽  
Vol 14 (2) ◽  
pp. 273-276 ◽  
Author(s):  
J.K. Campbell ◽  
J.P. Matthews ◽  
J.F. Seymour ◽  
M.M. Wolf ◽  
S.K. Juneja
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Diffuse Large Cell Lymphoma ◽  
Large Cell Lymphoma

scholarly journals Successful treatment of post chemotherapy esophageal cicatricial atresia in a pediatric patient with anaplastic large cell lymphoma through minimally invasive esophagectomy: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yuto Hozaka ◽  
Ken Sasaki ◽  
Takuro Nishikawa ◽  
Shun Onishi ◽  
Masahiro Noda ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Esophageal Atresia ◽  
Cell Lymphoma ◽  
Allogeneic Bone Marrow Transplantation ◽  
Oral Intake ◽  
Large Cell ◽  
Thoracic Esophagus ◽  
Allogeneic Bone ◽  
Large Cell Lymphoma ◽  
Middle Thoracic Esophagus

Abstract Background Anaplastic large cell lymphoma (ALCL) is a CD30-positive T-cell lymphoma, which is a rare type of non-Hodgkin lymphoma. ALCL rarely presents in the gastrointestinal tract, and the esophageal involvement in of ALCL is extremely rare. Case presentation An 11-year-old boy who complained of abdominal pain and cough was diagnosed with ALK-positive ALCL on the basis of systemic lymphadenopathy findings and immunohistochemistry results of pleural effusion. Although remission was observed after chemotherapy at 5 months after diagnosis, dysphagia persisted, and esophagoscopy revealed a severe stricture in the middle thoracic esophagus. At 9 months after diagnosis, allogeneic bone marrow transplantation was performed to ensure that complete remission was maintained; however, dysphagia and saliva retention did not improve. Approximately 10 months after diagnosis, esophagoscopy revealed a blind end in the middle thoracic esophagus, similar to that in congenital esophageal atresia. Subsequently, we performed minimally invasive subtotal esophagectomy under thoracoscopy and laparoscopy and gastric conduit reconstruction via the retrosternal route more than 2 years after allogeneic bone marrow transplantation. The final pathological diagnosis was esophageal atresia with esophagitis, with no malignancy. During postoperative evaluation, the patient required swallowing training for a few months, although no major complications were noted. Oral intake was possible, and complete remission was maintained at 14 month post-surgery. Conclusions Oncologists must consider the possibility of acquired esophageal cicatricial atresia as a complication during chemotherapy for ALCL. If esophageal obstruction or esophageal atresia occur and if remission is maintained, esophagectomy and esophageal reconstruction are useful treatment options for maintaining oral intake.

Circulating Antibodies to ALK Inversely Correlat with Relapse Risk and Circulating Tumor Cells in Children and Adolescents with ALK-Positive Anaplastic Large Cell Lymphoma

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2831-2831
Author(s):  
Karen Pulford ◽  
Christine Damm-Welk ◽  
Birgit Burkhardt ◽  
Martin Zimmerman ◽  
Alfred Reiter ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Immune Response ◽  
Tumor Cells ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Autoantibody Response ◽  
Antibody Titers ◽  
Circulating Antibodies ◽  
Large Cell Lymphoma ◽  
Alk Positive

Abstract Tumour-associated antigens (TAAs) recognised by patients’ immune systems may be of prognostic relevance and also represent new immunotherapeutic targets. Circulating antibodies and T-cell responses to the TAA anaplastic lymphoma kinase (ALK) have been detected in patients with ALK-positive anaplastic large cell lymphoma (ALCL) (Pulford et al. Blood2000, 96:1605–7; Ait-Tahar et al. Int J Cancer2006, 118:688–95; Cancer Res2007, 65:1891–901). Their exact significance with regard to prognosis is, however, unclear at present. In contrast, and unusually for non-Hodgkin’s lymphoma, low numbers of circulating tumor cells (CTCs) expressing nucleophosmin (NPM)-ALK-transcripts at diagnosis in bone marrow or blood confers an unfavourable prognosis (Damm-Welk et al. Blood2007, 110:670–7). The current study was performed to address whether there was any correlation between the magnitude of the autoantibody response to ALK with prognosis and the levels of CTCs at diagnosis in a cohort of uniformly treated children and adolescents with ALK-positive ALCL for whom full clinical data was available. The anti-ALK-antibody titers were analyzed in initial serum or plasma samples from 86 patients and copies of NPM-ALK in initial bone marrow (n=61) and/or blood samples (n=53). The children were treated according to the NHL-BFM95 and ALCL99 trials carried out between 1996 and 2006. Antibody titers against ALK and copies of NPM-ALK were measured using ALK transfectants and quantitative RT-PCR as previously described (Pulford et al. Blood2000, 96:1605–7; Damm-Welk et al. Blood2007, 110:670–7). Circulating antibodies to ALK were detected in 80/86 (93%) of patients studied. The titers ranged between 1/50 and ≥1/60750. The median follow-up of the patients was 4.6 years (range 1.4–10.4 years). Antibody titers &lt;1/60750, detected in 61 patients (71%), significantly correlated with advanced stage, mediastinal or visceral involvement. The 5 year event free survival rate (pEFS) of 25 patients with antibody titres ≥1/60750 was 88+/− 0.06% compared to 51+/−0.07% for 61 patients with titres less than 1/60750 (p&lt;.003). Among those patients mounting an antibody response, higher antibody titers were significantly associated with lower cumulative incidence of relapses (CI-R): 17 patients with a titer between 1/50 and &lt;1/2025 had a CI-R of 74±12% compared to a CI-R of 32±8% for 38 patients with titers between 1/2025 and &lt;1/60750 and a CI-R of 12±7% for 25 patients with titers ≥1/60750 (p&lt;.001). There was a significant inverse correlation between the magnitude of antibody titers and CTCs in 61 patients studied for the presence of both autoantibodies and CTC in bone marrow. None of the 20 patients with a high antibody titer (≥1/60750) had more than 10 copies NPM-ALK/104 copies ABL in bone marrow compared to 13 of 41 patients with lower antibody titers (p=.003). Comparison of antibody titers with CTCs in peripheral blood led to a similar grouping. In conclusion, the current study shows, for the first time, that the magnitude of the autoantibody response to ALK is inversely correlated with the relapse risk and disease dissemination in ALK-positive ALCL. Our results, therefore, provide clinical evidence that a strong immune response to ALK may control the progression of ALCL supporting the possibility that CTCs are a secondary phenomenon due to a limited anti-tumor immune response. These results also support the use of ALK as an immunotherapeutic target in ALCL.

Hematologic findings predictive of bone marrow disease in dogs with multicentric large-cell lymphoma

2014 ◽  
Vol 43 (4) ◽  
pp. 505-512 ◽  
Author(s):  
Emily C. Graff ◽  
Elizabeth A. Spangler ◽  
Annette Smith ◽  
Melody Denhere ◽  
Minerva Brauss
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Bone Marrow Disease ◽  
Large Cell Lymphoma
Sign in / Sign up

Export Citation Format

Share Document